Titre : Inhibiteurs de la libération d'acétylcholine

Inhibiteurs de la libération d'acétylcholine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cross-Over Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la libération d'acétylcholine : Questions médicales les plus fréquentes", "headline": "Inhibiteurs de la libération d'acétylcholine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs de la libération d'acétylcholine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-06", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs de la libération d'acétylcholine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Agents cholinergiques", "url": "https://questionsmedicales.fr/mesh/D018678", "about": { "@type": "MedicalCondition", "name": "Agents cholinergiques", "code": { "@type": "MedicalCode", "code": "D018678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.577.120" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la libération d'acétylcholine", "alternateName": "Acetylcholine Release Inhibitors", "code": { "@type": "MedicalCode", "code": "D065087", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ikunobu Muramatsu", "url": "https://questionsmedicales.fr/author/Ikunobu%20Muramatsu", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan." } }, { "@type": "Person", "name": "Junsuke Uwada", "url": "https://questionsmedicales.fr/author/Junsuke%20Uwada", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan." } }, { "@type": "Person", "name": "Kiyonao Sada", "url": "https://questionsmedicales.fr/author/Kiyonao%20Sada", "affiliation": { "@type": "Organization", "name": "Division of Genomic Science and Microbiology, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan." } }, { "@type": "Person", "name": "Takayoshi Masuoka", "url": "https://questionsmedicales.fr/author/Takayoshi%20Masuoka", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan." } }, { "@type": "Person", "name": "Takashi Yazawa", "url": "https://questionsmedicales.fr/author/Takashi%20Yazawa", "affiliation": { "@type": "Organization", "name": "Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Acute Insulin Secretory Effects of a Classic Ketogenic Meal in Healthy Subjects: A Randomized Cross-Over Study.", "datePublished": "2023-02-23", "url": "https://questionsmedicales.fr/article/36904127", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/nu15051119" } }, { "@type": "ScholarlyArticle", "name": "Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study.", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/35797804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.msard.2022.104004" } }, { "@type": "ScholarlyArticle", "name": "Effects of foam rolling and strength training on post exercise hypotension in normotensive women: A cross-over study.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37301562", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbmt.2023.04.017" } }, { "@type": "ScholarlyArticle", "name": "Effect of Wearing N95 Mask on the Quality of Chest Compressions in Prehospital Emergency Personnel: A Cross-over Study.", "datePublished": "2022-07-14", "url": "https://questionsmedicales.fr/article/35759255", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/10903127.2022.2095066" } }, { "@type": "ScholarlyArticle", "name": "Palatability of two different formulations of urea for the treatment of hyponatremia: A double-blind, randomized, cross-over study.", "datePublished": "2023-11-09", "url": "https://questionsmedicales.fr/article/38057026", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clnesp.2023.10.037" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Effets physiologiques des médicaments", "item": "https://questionsmedicales.fr/mesh/D045505" }, { "@type": "ListItem", "position": 5, "name": "Agents neuromédiateurs", "item": "https://questionsmedicales.fr/mesh/D018377" }, { "@type": "ListItem", "position": 6, "name": "Agents cholinergiques", "item": "https://questionsmedicales.fr/mesh/D018678" }, { "@type": "ListItem", "position": 7, "name": "Inhibiteurs de la libération d'acétylcholine", "item": "https://questionsmedicales.fr/mesh/D065087" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs de la libération d'acétylcholine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la libération d'acétylcholine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs de la libération d'acétylcholine", "description": "Comment diagnostiquer une inhibition de l'acétylcholine ?\nQuels tests sont utilisés pour évaluer l'acétylcholine ?\nQuels symptômes indiquent une inhibition d'acétylcholine ?\nLes antécédents médicaux sont-ils importants ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs de la libération d'acétylcholine", "description": "Quels sont les symptômes courants d'une inhibition ?\nL'inhibition affecte-t-elle la cognition ?\nY a-t-il des symptômes respiratoires associés ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on avoir des symptômes digestifs ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs de la libération d'acétylcholine", "description": "Peut-on prévenir l'inhibition d'acétylcholine ?\nL'alimentation joue-t-elle un rôle ?\nL'exercice physique est-il bénéfique ?\nLe stress peut-il aggraver l'inhibition ?\nDes contrôles réguliers sont-ils nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs de la libération d'acétylcholine", "description": "Quels traitements sont disponibles pour l'inhibition ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires aux traitements ?\nLa rééducation est-elle recommandée ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs de la libération d'acétylcholine", "description": "Quelles complications peuvent survenir ?\nL'inhibition peut-elle entraîner des hospitalisations ?\nY a-t-il un risque de décès ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs de la libération d'acétylcholine", "description": "Quels sont les facteurs de risque d'inhibition ?\nL'âge est-il un facteur de risque ?\nLes médicaments peuvent-ils influencer le risque ?\nLe mode de vie affecte-t-il le risque ?\nLes infections virales sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Cross-Over+Studies&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une inhibition de l'acétylcholine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests neurologiques et l'évaluation des symptômes cliniques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'acétylcholine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests électromyographiques et des analyses sanguines peuvent être utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent une inhibition d'acétylcholine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la faiblesse musculaire et la fatigue peuvent indiquer une inhibition." } }, { "@type": "Question", "name": "Les antécédents médicaux sont-ils importants ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents médicaux aident à identifier des causes potentielles d'inhibition." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie cérébrale peut aider à exclure d'autres pathologies neurologiques." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une inhibition ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, fatigue, et troubles de la coordination." } }, { "@type": "Question", "name": "L'inhibition affecte-t-elle la cognition ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des troubles de la mémoire et de la concentration." } }, { "@type": "Question", "name": "Y a-t-il des symptômes respiratoires associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des difficultés respiratoires peuvent survenir en cas d'inhibition sévère." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes digestifs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des nausées et des troubles gastro-intestinaux peuvent se manifester." } }, { "@type": "Question", "name": "Peut-on prévenir l'inhibition d'acétylcholine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures préventives incluent un mode de vie sain et la gestion du stress." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée riche en antioxydants peut soutenir la santé neuronale." } }, { "@type": "Question", "name": "L'exercice physique est-il bénéfique ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la fonction musculaire et nerveuse." } }, { "@type": "Question", "name": "Le stress peut-il aggraver l'inhibition ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les symptômes d'inhibition d'acétylcholine." } }, { "@type": "Question", "name": "Des contrôles réguliers sont-ils nécessaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de surveiller l'évolution et d'ajuster les traitements." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour l'inhibition ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments anticholinestérasiques et des thérapies physiques." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent améliorer les symptômes et la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées et des crampes peuvent survenir." } }, { "@type": "Question", "name": "La rééducation est-elle recommandée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation physique peut aider à renforcer les muscles et améliorer la fonction." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles respiratoires et des crises musculaires." } }, { "@type": "Question", "name": "L'inhibition peut-elle entraîner des hospitalisations ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des cas graves peuvent nécessiter une hospitalisation pour surveillance." } }, { "@type": "Question", "name": "Y a-t-il un risque de décès ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Dans des cas extrêmes, l'inhibition sévère peut entraîner des risques mortels." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'inhibition ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des maladies auto-immunes, des infections et des antécédents familiaux." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé est un facteur de risque pour les troubles de la libération d'acétylcholine." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils influencer le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent augmenter le risque d'inhibition d'acétylcholine." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les infections virales sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections virales peuvent déclencher des troubles de la libération d'acétylcholine." } } ] } ] }

Sources (10000 au total)

Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study.

Upper limb dysfunctions are common in people with multiple sclerosis (PwMS) and lead to limitations in activities of daily living. In this study, we investigated the feasibility and effects of an imme... A total of 20 participants were included in a cross over study with two arm sequences: Treatment-Waiting List (T-WL; N = 9) and Waiting List-Treatment (WT-T; N = 11). T-WL sequence performed 12 sessio... We observed clinical and statistical improvements for BBT, with an overall between-sequence difference of 8.6 ± 2.6 blocks (p < 0.01) favoring treatment period in the less affected side, and a not sig... An immersive VR-based approach resulted useful to improve gross manual dexterity in the less affected limb in PwMS. However, such improvement did not translate into modifications in terms of self-repo...

Effect of Wearing N95 Mask on the Quality of Chest Compressions in Prehospital Emergency Personnel: A Cross-over Study.

To evaluate the effect of wearing an N95 mask on the quality of chest compression and fatigue of prehospital emergency personnel during cardiopulmonary resuscitation (CPR).... Twenty-four eligible participants were recruited. Participants' age, sex, height, and weight were recorded. After completing the CPR training and examination, participants were tested twice, wearing s... Compared to wearing surgical masks, participants wearing N95 masks had significantly lower quality of chest compression, including compression frequency (98.3 ± 4.9 bpm vs 104.0 ± 6.0 bpm, P < 0.001),... This study showed that the use of an N95 mask by prehospital emergency personnel during the performance of chest compressions resulted in a reduction of compression quality and increased clinician fat...

Palatability of two different formulations of urea for the treatment of hyponatremia: A double-blind, randomized, cross-over study.

Hyponatremia (HN) is the most common disorder of electrolytes encountered in clinical practice. Considering that HN is associated with high morbidity and mortality, it is important to identify treatme... Thirty-six healthy subjects (18 female and 18 male, median age 55 years) were enrolled in the study and randomized to consume 7 g of formulation A (commercial formulation) or formulation B (galenic fo... The commercial formulation was globally more appreciated than the galenic one, in terms of smell, taste, and aftertaste. The commercial formulation was better accepted as a potential treatment in 44 %... The clinical trial confirmed the better palatability of the commercial oral urea formulation, containing citrus flavor, which therefore represents a therapeutic strategy that could improve adherence t...

Effects of α-lactalbumin on strength, fatigue and psychological parameters: a randomised double-blind cross-over study.

The neurotransmitter serotonin has a strong effect on behaviour and motor control. Regarding motor control, serotonin contributes to the development of fatigue and is also involved in the ability of m... Using a randomised double-blind cross-over design, 16 healthy participants performed plantar flexor and handgrip maximal voluntary contractions, a 30-s submaximal handgrip contraction, and a plantar f... α-Lactalbumin decreased force steadiness by 25% during the sustained submaximal handgrip contraction (p < 0.01) and induced greater fatigue (15% reduction in total torque-time integral, p = 0.01) duri... 40 g of α-lactalbumin increased handgrip force variability and reduced performance during fatiguing muscle contractions but did not influence brief maximal contractions or psychological parameters in ...

Cigarette pack size and consumption: a randomized cross-over trial.

Smoking fewer cigarettes per day may increase the chances of stopping smoking. Capping the number of cigarettes per pack is a promising policy option, but the causal impact of such a change is unknown... This randomized controlled cross-over trial had two 14-day intervention periods with an intervening 7-day period of usual behaviour. Participants purchased their own cigarettes. They were instructed t... Canada.... Participants were adult smokers who smoked from pack sizes of 25, recruited between July 2020 and June 2021. Of 252 randomized, 240 (95%) completed the study and 236 (94%) provided sufficient data for... Cigarettes smoked per participant per day.... Participants smoked fewer cigarettes per day from packs of 20 cigarettes [n = 234, mean = 15.7 standard deviation (SD) = 7.1] than from packs of 25 (n = 235, mean = 16.9, SD = 7.1). After adjusting fo... Smoking from packs of 20 compared with 25 cigarettes reduced the number of cigarettes smoked per day....

Effects of dexmedetomidine on pharyngeal swallowing and esophageal motility-A double-blind randomized cross-over study in healthy volunteers.

Sedative agents increase the risk of pulmonary aspiration, where an intact swallowing function is an important defense mechanism. Dexmedetomidine is an α... To determine the effects of dexmedetomidine on pharyngeal swallowing and esophageal motility, nineteen volunteers were included in this double-blinded, randomized placebo-controlled cross-over study. ... On pharyngeal swallowing, dexmedetomidine affected the upper esophageal sphincter with decreased pre- and post-swallow contractile pressures and an increase in residual pressure during swallow-related... Dexmedetomidine induces effects on pharyngeal swallowing and esophageal motility, which should be considered in clinical patient management and also when a sedative agent for procedural sedation or fo...

Effect of beta-blockers on multiple haemodynamics in cirrhosis: A cross-over study by MR-imaging and hepatic vein catheterization.

Non-selective beta-blockers (NSBB) are widely used in the treatment of patients with cirrhosis. Only about 50% respond with a sufficient reduction in their hepatic venous pressure gradient (HVPG) and ... A prospective cross-over study of 39 patients with cirrhosis. Patients underwent hepatic vein catheterization and MRI with assessments of HVPG, cardiac function, systemic and splanchnic haemodynamics ... Propranolol induced significant decreases in cardiac output (-12%) and blood flow of all vascular compartments, with the largest reductions seen in the azygos venous (-28%), portal venous (-21%), sple... The changes in cardiac, systemic and splanchnic haemodynamics did not differ between NSBB responders and non-responders. The effects of acute NSBB blockade on renal flow seem to depend on the severity...